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ABSTRACT
Neurofibromatosis type 1 (NF1) is associated with neurocognitive deficits that can impact every-
day functioning of children, adolescents, and adults with this disease. However, there is little
agreement regarding measures to use as cognitive endpoints in clinical trials. This article de-
scribes the work of the Neurocognitive Committee of the Response Evaluation in Neurofibroma-
tosis and Schwannomatosis (REiNS) International Collaboration. The goal of this committee is to
identify standardized and specific cognitive assessment tools for use in NF clinical trials. The
committee first identified cognitive domains relevant to NF1 and prioritized attention as the first
domain of focus given prior and current trends in NF1 cognitive clinical trials. Performance meas-
ures and behavioral rating questionnaires of attention were reviewed by the group using estab-
lished criteria to assess patient characteristics, psychometric properties, and feasibility. The
highest rated tests underwent side-by-side comparison. The Digit Span subtest from the Wechsler
scales was given the highest ratings of the performance measures due to its good psychometrics,
feasibility, utility across a wide age range, and extensive use in previous research. The Conners
scales achieved the highest ratings of the behavioral questionnaires for similar reasons. Future
articles will focus on other cognitive domains, with the ultimate goal of achieving agreement for
cognitive endpoints that can be used across NF clinical trials. Neurology® 2016;87 (Suppl 1):S21–S30
GLOSSARY
ADHD-RS 5 ADHD Rating Scale; CAARS 5 Conners Adult ADHD Rating Scale; COA 5 clinical outcome assessment; DS 5
Digit Span; FDA 5 Food and Drug Administration; FSIQ 5 full-scale IQ;MATRICS 5Measurement and Treatment Research
to Improve Cognition in Schizophrenia; NF1 5 neurofibromatosis type 1; ObsRO 5 observer-reported outcome; PerfO 5
performance outcome; REiNS 5 Response Evaluation in Neurofibromatosis and Schwannomatosis; TEA 5 Test of Everyday
Attention; TEA-Ch 5 Test of Everyday Attention for Children.
Neurocognitive sequelae in neurofibromatosis type 1 (NF1) have been well-documented and
result in significant morbidity and dysfunction in children, adolescents, and adults with the dis-
ease.1–7 Research has documented phenotypic patterns of cognitive dysfunction in NF1, as well
as the functional impact these deficits have on individuals in naturalistic settings such as school
and work.8–11
Despite the high prevalence and significant morbidity of cognitive impairments, few interven-
tion trials have targeted cognitive dysfunction as a primary endpoint. It is vital to establish stand-
ards to evaluate therapies for the treatment of cognitive deficits, and to work towards acceptance of
cognition as a therapeutic target. Behavioral interventions to prevent or remediate cognitive def-
icits would benefit from consensus on cognitive endpoints as well. With these goals in mind, the
Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) Neurocognitive Sub-
committee was formed to identify standardized, specific cognitive endpoints for clinical trials.
While human clinical trials targeting cognition in NF1 have been relatively slow to emerge,
murine models of cognitive dysfunction have been ongoing since the original work of Silva
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et al.12 Animal models have provided guidance
in the development of clinical trials, providing
pathway level hypotheses for translation to
human trials.13 However, the translation from
mouse behavior to human cognitive models
has been challenging due to the range and
complexity of human cognition and the lack
of consensus regarding how best to measure
cognition for clinical trials endpoints.
The diversity of approaches to measure-
ment of cognitive outcomes is illustrated when
reviewing the cognitive clinical trials that have
been completed or are ongoing. As of 2016,
there have been 9 clinical trials targeting
cognitive outcomes in NF1, each employing
a different battery of cognitive tests despite
targeting the same primary constructs of atten-
tion, working memory, visual memory, intelli-
gence, and emotional/behavioral functioning
(table 1). The lack of evaluative and analytic
consistency and standards significantly hinders
our ability to adequately assess therapeutic effi-
cacy, to combine smaller samples to yield
higher power to detect effects, and limits the
generalizability of findings.
Other disease groups have developed consen-
sus and standards for evaluating cognitive out-
comes to support the development of new
therapies.14,15 Perhaps the most successful work
in this area has been the work of the Measure-
ment and Treatment Research to Improve
Cognition in Schizophrenia (MATRICS) col-
laboration.15–17 The MATRICS group posited
that the lack of approved treatments for cogni-
tive dysfunction in schizophrenia was directly
related to the use of diverse assessment ap-
proaches across clinical trials. This problem sig-
nificantly limited the ability to adequately
evaluate a drug’s effectiveness in treating cogni-
tive deficits, especially for governmental organ-
izations tasked with oversight.15 TheMATRICS
group identified specific criteria critical for
determining appropriate assessment tools for
endpoints in clinical trials of schizophrenia,
including (1) good test-retest reliability, (2) high
utility for repeated assessment, (3) a relationship
with functional outcomes, (4) sensitivity to
a pharmacologic agent, and (5) practicality.15
Co–primary endpoints that assess the impact
of cognitive functioning on everyday living
skills were also emphasized. These measures
complement the primary outcome of cognitive
performance and provide essential evidence of
therapeutic utility.
Following the example of other disease-
specific groups, this article is the first of its kind
to provide recommendations for cognitive out-
comes for clinical trials in NF1. This will sup-
port the promotion of cognition as a target for
interventions in NF1 and encourage the devel-
opment of novel compounds and behavioral
therapies targeting these impairments.
CONSIDERATIONS AND CHALLENGES There are
challenges associated with efficiently and effectively
developing a standardized cognitive test battery for
use in clinical trials. First, there are many cognitive do-
mains that could conceivably be appropriate for clinical
trials endpoints and within many of these domains are
subdomains of skills, each of which has the potential to
be a specific therapeutic target (table 2). For example,
full-scale IQ (FSIQ) is composed of multiple distinct
functional areas including verbal and nonverbal
reasoning, working memory/attention, and processing
speed. Given the multifactorial nature of intellect,
global measures such as FSIQ will likely lack the
sensitivity to be ideal primary endpoints, particularly
when there are discrepancies between the various
functions assessed, as is common in NF1.
Second, many tests are available to assess each cog-
nitive domain. Each test varies in its reliability and
validity for specific populations, as well as its feasibil-
ity for use in clinical trials, including use for shorter
test-retest periods. Developmental factors are another
significant challenge for cognitive researchers. Few cog-
nitive tests or symptom checklists are intended to span
broad age ranges, with most meant for specific use
with preschoolers, school-age children/adolescents, or
adults. It will be important to include young children
in clinical trials; however, preschool measures are
sparse compared to those available for other age ranges,
and will require careful consideration. Finally, there is
virtually no literature about cognitive effects of aging in
NF1, such that it is unclear which measures are most
effective at characterizing cognitive functioning in old-
er adulthood. Based on these considerations, we prior-
itized the domain of attention, a highly prevalent
problem in NF1, which has been evaluated in recent
or ongoing clinical and preclinical trials. Further, the
current work will focus on school-aged children ($6
years) through adults. We will review and make rec-
ommendations for the preschool age group, as well as
offer methodologic and statistical approaches to longi-
tudinal designs across age groups (e.g., preschool into
school age, and school age into adulthood), in future
publications.
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METHODS Goals of the REiNS Neurocognitive
Committee. The goals of this working group are to (1) critically
and scientifically review standardized cognitive assessment tools
for use in NF1 clinical trials, (2) provide recommendations
for a core test bank of neurocognitive measures across cognitive
domains to be utilized in NF1 clinical trials to enhance consis-
tency across trials and sites, and (3) function as a resource for re-
searchers in the development of cognitive protocols. By providing
this guidance, we hope to support the development and evalua-
tion of novel therapeutics for the treatment of cognitive deficits
in children and adults with NF1.
Food and Drug Administration (FDA) clinical outcome
assessment (COA). To select clinically useful cognitive endpoints,
we have been guided by recommendations regarding COAs.18 These
COAs must be appropriately defined and reliable for the evaluation
of a specific condition of interest in a specific context of use, based on
available evidence. Qualification as a COA indicates that a tool can
be relied upon to measure a distinct concept and have a specific
interpretation and application in drug development. The FDA has
deemed 2 areas of specific relevance: performance outcome (PerfO)
and observer-reported outcome (ObsRO) assessments. PerfO fall
into 2 categories: (1) paper-pencil tests and (2) computerized
tasks/batteries. ObsRO include behavior rating questionnaires
completed by caretakers (parents, guardians) and teachers, which
assess a child’s behavioral/emotional functioning or cognitive
functions including attention, impulsivity, executive function, and
adaptive function, in their everyday environment.Within each of the
Table 1 Clinical trials targeting cognitive outcomes in neurofibromatosis type 1
Study
referencea Intervention/design No.
Primary construct of interest
and outcome measures Other outcome measures Results
34 Methylphenidate (single-arm) 93 Attention: TOVA; CBCL Not applicable Significant improvement on TOVA
and improvement after 1 year on
CBCL
35 Simvastatin (randomized
placebo controlled)
62 Long-term visual memory: RCFT
(Delayed Recall); attention:
Cancellation Test (speed)
RCFT (Copy); Cancellation Test
(SD); Stroop; Block Design;
Object Assembly; VMI; JLO
No significant improvement
following treatment with the
exception of object assembly
(specifically in the group with lower
baseline functioning on the task)
36 Single-arm lovastatin (phase I/II;
on treatment 3 months)
24 Short- and long-term visual and verbal
memory: WRAML-2 (Story, Design, and
Picture Memory), CVMT, CVLT-C;
attention: TEA-Ch (Score!, Sky Search,
Sky Search Dual Task, Creature
Counting)
JLO; Grooved Pegboard Some improvements in memory with
13%–39% exceeding base rate
change (80% CI) from pretreatment
to posttreatment evaluation,
indicative of clinically meaningful
change following treatment for at
least this subgroup of participants
37 Methylphenidate (placebo-
controlled)
80 Psychological: STAI-C; CDI No results published or presented
38 Randomized placebo-controlled
simvastatin (on treatment
12 months)
84 Global functioning/intelligence: WISC-
III-NL (full-scale intelligence); attention
and emotional: CBCL (Attention
Problems and Internalizing Problems
scales)
RCFT (Delayed Recall); Stroop;
Grooved Pegboard; TRF; YSR;
CHQ (Parent)
No significant improvement
following treatment
39 Methylphenidate (placebo-
controlled, crossover)
39 Attention: CPRS-3 CTRS-3 Significant improvement in
symptoms on CPRS
40 Lovastatin (placebo-controlled) 44 Nonverbal declarative memory: BVMT;
working memory: Letter-Number
Sequencing
Digit Cancellation; HVLT;
WISC-III Object Assembly;
CBCL/YASR
Significant improvement on Letter-
Number Sequencing, HVLT, and
categorical verbal generation;
significant improvement in adult
patients on internalizing symptoms;
all other primary and secondary
outcomes not significant
27 Randomized placebo-controlled
lovastatin (STARS)
146 Visual working memory: CANTAB
(Paired Associates Learning);
attention: TEA-Ch (Score!)
CANTAB (Spatial Working
Memory, Stockings of
Cambridge, Stop Signal Task,
Motor); TEA-Ch (Sky Search,
Sky Search Dual Task, Creature
Counting); JLO; WISC-III (Object
Assembly); CPT-II; COWAT
Results pending
41 Lamotrigine (randomized
placebo-controlled)
Active Intellectual: WISC-III (performance IQ) WISC-III (full IQ); SA-Dots;
BRIEF; ADHD Questionnaire;
PAL (CANTAB); VMI-6; MVPT-3;
Grooved Pegboard
Active
Abbreviations: ADHD 5 attention-deficit/hyperactivity disorder; BRIEF 5 Behavior Rating Inventory for Executive Function; BVMT 5 Brief Visuospatial
Memory Test–Revised; CANTAB5 Cambridge Neuropsychological Test Automated Battery; CBCL5 Child Behavior Checklist; CDI5 Children’s Depression
Inventory; CHQ 5 Child Health Questionnaire; CI 5 confidence interval; COWAT 5 Controlled Oral Word Association Test; CPRS/CTRS 5 Conners’ Parent
Rating Scale/Conners’ Teacher Rating Scale; CPT-II 5 Conners Continuous Performance Test, Second Edition; CVLT-C 5 California Verbal Learning Test
for Children; CVMT 5 Continuous Visual Memory Test; HVLT 5 Hopkins Verbal Learning Test; JLO 5 Judgment of Line Orientation; MVPT-3 5 Motor-Free
Visual Perception Test, Third Edition; PAL 5 Paired Associative Learning; RCFT 5 Rey Complex Figure Test; SA-Dots 5 Sustained Attention Dots of the
Amsterdam Neuropsychological Tasks; STAI-C 5 State Trait Anxiety Inventory for Children; STARS 5 A Randomized Placebo-Controlled Study of Lova-
statin in Children With Neurofibromatosis Type 1; TEA-Ch 5 Test of Everyday Attention for Children; TOVA 5 Test of Variables of Attention; TRF 5
Teacher Report Form; VMI 5 Beery Test of Visual-Motor Precision; WISC 5Wechsler Intelligence Scale for Children; WRAML5Wide Range Assessment of
Memory and Learning, Second Edition; YSR/YASR 5 Youth Self-Report/Young Adult Self Report.
a Literature search included PubMed and Clinicaltrials.gov.
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cognitive domains being evaluated, we provide recommendations
for both performance and observational measures, which may
serve as co–primary outcome tools in NF1 clinical trials to evaluate
their impact on everyday function, as has been recommended by
the FDA.19
Current clinical trials. We completed a literature search for
past and current pharmacologic cognitive clinical trials in NF1
in order to summarize the literature and document the diversity
of assessment instruments utilized for the same or very similar
primary outcome constructs. We performed several searches to
include PubMed.gov and ClinicalTrials.gov. Using the search
terms “neurofibromatosis type 1 cognitive clinical trial” and
“neurofibromatosis type 1 methylphenidate” identified 8
current or complete/published trials. We were made aware of
a ninth pharmacologic trial that was accepted for publication
but ahead of print, which was included.
Identification of cognitive domains and tools for review.
Because of the extensive number of cognitive domains and asso-
ciated assessment tools, it would be prohibitive to complete an
exhaustive review of all published tests. In order to increase the
feasibility of achieving the goals of the working group, a 2-step
process was implemented. The first phase involved identifying
all cognitive domains relevant to NF1 and prioritizing those
domains, with the highest importance associated with the known
or likely targets for cognitive clinical trials now and in the near
future. The second phase included surveying experienced NF1
cognitive researchers and clinicians, who were asked to list the
assessment instruments within each cognitive domain that they
use most consistently and consider to be reliable and sensitive
tools with the NF1 population. The list of potential assessment
tools was summarized and discussed to establish a final pool of
instruments to be reviewed in order to establish a core set of test
instruments. This manuscript provides recommendations for
paper-pencil tests (PerfO) and behavioral questionnaires (ObsRO)
of attention in NF1. Because computerized test batteries evaluate
a range of cognitive domains, recommendations for computerized
test batteries that include tests of attention will be included in
a future article.
Establishing evaluation criteria. Based on a systematic review
process established by the REiNS Patient-Reported Outcomes
Committee, we developed the Cog-RATE form as a means of
reviewing cognitive tests.20 The form enabled the committee to
rate each measure on 6 key criteria: patient characteristics (age
range for measure; use with specific populations), use in
published studies, domains assessed, availability of standard
scores, psychometric characteristics, and feasibility for clinical
trials. The Neurocognitive Committee decided to give greater
consideration to each test’s psychometric properties, patient
characteristics, and feasibility of use in clinical trials, which
were considered the most relevant for clinical trials. The process
utilized by our committee in reviewing each tool is provided in
table 3.
RESULTS We reviewed 5 performance-based measures
and 5 observation measures of attention available for
school-aged children through adults (age 6 and up;
table 4). Of the 5 performance measures considered,
2 tasks, Spatial Span from the Wechsler scales and
Spatial Span from the Stanford-Binet, did not
remain under consideration given their limited use
in previous NF1 clinical studies and limitations in
specificity.21,22
Three measures were sufficiently rated to remain
under consideration: Digit Span (DS) from the
Wechsler scales (Wechsler Intelligence Scale for
Table 2 Cognitive domains relevant to neurofibromatosis clinical trials
Cognitive domain Description Subdomains
Attention The ability to select and focus on relevant information while
filtering out irrelevant information
Vigilance (engagement, focus); sustained attention; attentional
shift (re-engagement)
Executive function An umbrella term for higher-order cognitive processes involved
in managing cognitive and behavioral resources to achieve a goal
Initiation; inhibition; monitoring (cognitive and behavioral);
working memory; strategic planning; organization; flexibility;
emotional regulation
Memory The ability to retain and recall information Encoding; consolidation; retrieval; (verbal and visual; short- and
long-term)
Processing speed The ability to complete tasks quickly, automatically, and fluently
Visual-spatial/visual-motor Visual-spatial skills include the ability to mentally manipulate 2D
and 3D objects, as well as determine spatial relationships
between objects; visual-motor skills are the ability to coordinate
motor movements with visual input
Mental rotation; visual closure; spatial orientation; object
localization; form/pattern discrimination; drawing/copying
Language Receptive language skills are the ability to understand language
heard or read; expressive language skills are the ability to put
thoughts into words and sentences in a way that makes sense
and is grammatically correct
Phonology—phonemic awareness, decoding, encoding (spelling
and reading); semantics—receptive (aural and written—to
include reading comprehension); expressive (oral and written—to
include spelling and composition); morphology—understanding
and producing grammatical aspects of language; pragmatics—
understanding social aspects of language; using social language
appropriately; syntax—understanding and using appropriate
sentence structure
Adaptive The ability to handle common life demands Community living; health and safety; self-care; leisure skills;
coping skills; social skills; functional communication; functional
academics; work skills; self-direction
Behavioral/emotional An individual’s mood and behavioral presentation Depression; anxiety; conduct problems; aggression; withdrawal;
atypical behaviors
Academics School-related skills Reading; reading comprehension; spelling; written expression;
math calculation; math problem-solving
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Children and Wechsler Adult Intelligence Scale), the
Test of Everyday Attention (TEA), and the TEA for
Children (TEA-Ch).23–26 The TEA-Ch and DS have
both been used in previous published clinical trials
with NF1 and demonstrated adequate psychometric
properties. As the TEA-Ch includes 9 different subt-
ests, we evaluated this measure in several ways: as
a complete battery including all 9 subtests, as a screen-
ing instrument of 4 subtests (Sky Search, Score!,
Creature Counting, and Sky Search Dual Task),
and as individual subtests. We reviewed the TEA as
a complete battery as well as by individual subtests,
particularly as they relate to continuity with the
TEA-Ch. These measures were then compared across
the primary evaluative factors.
Although the TEA-Ch (and the TEA, the adult
version of the test) is a feasible and sensitive assess-
ment of attention, it lacks normative data in individ-
uals 16 and 17 years of age. In prior studies, this gap
has resulted in arbitrary truncation of inclusion crite-
ria related to age.27 In addition, there is a lack of
parallel subtests between the TEA-Ch and TEA, sig-
nificantly limiting the use of these tools across age
ranges in clinical trials. For these reasons, the com-
mittee could not recommend the tools as primary
outcome measures in NF1 clinical trials.
DS can be used as a combined performance score,
or separated into Forward, Backward, and Sequenc-
ing components. The committee ultimately chose
DS as the recommended PerfO measure of attention
given its utility in a wide range of ages (6 years
through adult), good feasibility (easily administered
in sites that have a Wechsler instrument), as well as
good psychometric properties, particularly test-retest
reliability. Because DS Backward and Sequencing
tap into aspects of executive function including work-
ing memory, the committee recommends the specific
use of DS Forward for the measurement of attention.
When using any performance-based test in preinter-
vention and postintervention designs, the risk of prac-
tice effects must always be considered. Previous
intervention trials using DS have found limited
Table 3 Review and rating process of cognitive tests and rating scales
Step 1: Identify cognitive measures to review per domain
Survey neurofibromatosis researchers and clinicians about cognitive measures they use
Identify other possible measures from personal knowledge or literature review
Review of a measure by one member helps decide if a full group review is needed
Step 2: Prepare for the review of a measure
Members use the Cog-RATE form to systematically review cognitive measures
One member is identified to serve as a lead reviewer for a measure
The lead reviewer and group chair review the literature about the measure
Relevant articles describing the measure and its use in validation/descriptive studies and clinical trials are posted on the group’s
document-sharing site 1–2 weeks prior to the call
Members review the scale and articles and rate each Cog-RATE criteria
Step 3: Group review and rating of a measure by conference call
Cog-RATE forms may be e-mailed to the chair if members cannot attend a call
Members provide and discuss their rating from 0 (lowest rating/unacceptable) to 3 (highest rating) for each of the 6 Cog-RATE
criteria; ratings are recorded
Discrepancies are discussed to make sure they are not based on lack of familiarity with the measure or not understanding all the
information
The mean of the ratings for each of the 6 criteria is computed; the overall score is the total mean of the 6 criteria
Strengths and weaknesses are summarized; notes are taken regarding any outstanding issues
Members discuss whether the measure could be recommended as a primary or secondary outcome measure
The group determines if any additional information is needed to reach a final decision and whether a measure needs to be brought
up for a second review
For newly developed measures, a future review is planned to consider new information
The top closely rated measures may be compared side-by-side in another meeting
Step 4: Post-call activities
The group chair provides notes to summarize the conference call
Final notes and the Cog-RATE form ratings are uploaded to the document-sharing site to document the group’s decision
Final recommendations are reviewed with the entire REiNS collaborative group at yearly meetings
Abbreviations: REiNS 5 Response Evaluation in Neurofibromatosis and Schwannomatosis.
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Table 4 Performance-based measures reviewed
Measures
Normative
data, n
Age range,
year:month Reliability (test-retest) Validity studies Pros Cons
Cog-RATE
overall group
rating
Digit Span WISC-IV23 2,200 6:0–16:11 No. 5 243; DS: r 5 0.81; DSF: r 5 0.79;
DSB: r 5 0.76; no. 5 4342; DS: r 5 0.74
Concurrent: WISC-III: r 5 0.77; WAIS-III:
r 5 0.73; construct: CMS attention/
concentration: r 5 0.72
Widely used in descriptive
and clinical studies,
including NF1 cohorts
Total score is a composite of DSF and DSB,
which measure different constructs43,44
2.62
WAIS-IV24 2,200 16:0–90:11 No. 5 293; DS: r 5 0.83; DSF: r 5 0.77;
DSB: r 5 0.71
Construct: CMS attention/
concentration; r 5 0.76; RBANS
attention; r 5 0.65 (WAIS-IV technical
manual)
TEA-Ch26 293 6:0–15:11 No. 5 5545; r 5 0.65–0.87 Structural equation model reveals
3 factors: selective, switching, and
sustained attention (regression
coefficients: 0.44–0.79); TEA-Ch
subtest correlations with IQ are
generally weak (all r , 0.31)
Used in clinical studies,
including NF1; numerous
subtests that allow
assessment across
different attentional
capacities
Normative data limited to 6–15 years, 11
months
2.44
TEA25 154 18:0–80:0 No. 5 11825; r 5 0.59–0.86 Construct: r 5 0.42–0.63 with other
established measures of attention
Numerous subtests that
allow assessment across
different attentional
capacities
Has not been used in NF1 clinical studies 2.18
Spatial Span (WISC-
IV Integrated)21
2,200 6:1–16:11 No. 5 17421; SPF: r 5 0.79; SPB: r 5 0.81 Discriminative: SSF and SSB scores for
ADHD and ASD standardization
samples are significantly lower than
matched control group
Total score is a composite of SPF and SPB,
and they appear to measure different
constructs46; floor effects in younger
children; not used in NF1 clinical studies
2.26
Block Span (Stanford
Binet-V)22
4,800 2:0–85:0 No. 5 35622; r 5 0.66–0.93 Construct: r 5 0.66–0.85 with the
Wechsler Scales (WPPSI-R, WISC-III,
WAIS-III)
Test specificity in question since other
factors can impact performance (e.g., visual
scanning and problems with motor control);
not used in NF1 clinical studies
2.42
Abbreviations: ADHD5 attention-deficit/hyperactivity disorder; ASD5 autism spectrum disorder; CMS5 Children’s Memory Scale; DS5 Digit Span; DSB5 Digit Span Backward; DSF5 Digit Span Forward; NF15
neurofibromatosis type 1; RBANS5 Repeatable Battery for the Assessment of Neuropsychological Status; SPB5 Spatial Span Backward; SPF5 Spatial Span Forward; SSB5 spatial span backward; SSF5 spatial
span forward; TEA-Ch 5 Test of Everyday Attention for Children; WAIS 5 Wechsler Adult Intelligence Scale; WISC 5 Wechsler Intelligence Scale for Children; WPPSI 5 Wechsler Preschool and Primary Scale of
Intelligence.
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Table 5 Observer-rated measures reviewed
Measures
Normative
data
Age range, year:
month Reliability Validity studies Pros Cons
Cog-RATE
overall group
rating
Conners 332 3,400 6:0–16:0 (parent/
teacher); 8:0–
18:0 (self-report)
Test-retest r 5 0.85 (parent); r 5 0.85
(teacher); r 5 0.79 (self-report);
interrater r 5 0.81 (parent); r 5 0.73
(teacher)
Confirmatory factor analyses revealed parent
and self-reports have adequate fit; teacher
version was slightly lower; acceptable between-
informant correlations: parent to teacher r 5
0.60; parent to self-report r 5 0.56; teacher to
self-report r 5 0.48; convergent and divergent
validity established with other measures of child
and adolescent psychopathology; moderate to
high discriminant validity reported in the manual
for the different scoring version of the Conners
3; probability of accurately predicting group
membership (e.g., ADHD vs non-ADHD, impulsive
vs hyperactive vs combined) ranged from 0.66
to 0.95
Previous version (CRS-R) has been used in
16 clinical trials (PubMed search term:
Conners’ Rating Scales–Revised); CRS-R has
been used in many cross-sectional studies,
including NF147; Scoring options for DSM-5
and DSM-IV-TR
Current version has
limited use in
published clinical
trials to date
2.65
CAARS33 2,000 181 (observer
and self-report)
Test-retest r 5 0.80–0.91 (self-report);
r 5 0.85–0.95 (observer)33
Confirmatory factor analyses for both self-
report and observer forms met criteria for good
fit; was able to discriminate between ADHD and
control group with an overall correct
classification rate of 85%; construct validity
examined using the WURS, r 5 0.37–0.67
Used in many cross-sectional and large
clinical trials
Not used in NF1
cohorts to date
2.30
ADHD Rating
Scale-IV31
2,000 6:0–18:0 (parent/
teacher)
Not available Consistent with the 2-factor model of ADHD
(inattention and hyperactive/impulsive);
differentiated children with impulsive and
combined subtypes from unaffected controls
Used in many cross-sectional and clinical
studies, including NF1 cohorts
Weak evidence of
convergent and
discriminant validity
reported using both
teacher and parent
versions48
2.65
Adult ADHD
Symptom Scale,
Self-Report49
720 17:0–501 Not available Not available Have been used in multiple descriptive
studies
Not used in NF1
cohorts to date
2.41
Vanderbilt ADHD
Diagnostic Parent
Rating Scale50
243 5:0–9:11 Not available Consistent with the 2-factor model of ADHD
(inattention and hyperactive/impulsive);
moderate concurrent validity with DISC-IV
r 5 0.79
Not widely used in
studies; no studies
identified within NF1
samples
1.72
Abbreviations: ADHD 5 attention-deficit/hyperactivity disorder; CAARS 5 Conners Adult ADHD Rating Scale; CSR-R 5 Conners Rating Scale–Revised; DISC-IV 5 Diagnostic Interview Schedule for Children, 4th
edition; DSM 5 Diagnostic and Statistical Manual of Mental Disorders; NF1 5 neurofibromatosis type 1; WURS 5 Wender Utah Rating Scale.
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practice effects in as short as a 6 week test-retest time
span, suggesting that DS can be used even over short
intervals.28,29 However, practice effects should always
be managed through study methodology (e.g., inclu-
sion of a control group) or statistical approaches, such
as the use of reliable change indices, which take into
account psychometric issues, practice effects, and
other sources of variance to ensure that change dem-
onstrated on tests is meaningful.30 In addition, the
DS, like many tests, has a truncated range of scores
that may limit the ability to detect change for indi-
viduals who are not impaired at baseline. Researchers
will need to take these considerations into account
when using this measure as a clinical trial endpoint.
Five observation attention scales were reviewed
(table 5). The 2 measures with the highest ratings
were the Conners scales and the ADHD Rating Scale
(ADHD-RS).31 The Conners scales include 2 ver-
sions: the Conners Parent Rating Scale–3 (ages 6
through 18) and the Conners Adult ADHD Rating
Scale (CAARS; age 18 and older).32,33 Similarly, the
ADHD-RS has child and adult rating forms. The
Vanderbilt ADHD Rating Scale was also considered,
but limitations related to a severely truncated age
range, limited use in studies generally, regionally
limited normative data, and lack of age-based stan-
dard scores removed the instrument from further
consideration.
In comparing the Conners scales and the
ADHD-RS, both received similar ratings. However,
the committee believed that the superior psychomet-
ric information available and the extensive use of the
prior version of the Conners scales in clinical trials
were significant advantages and the Conners scales
were therefore chosen for recommendation. In addi-
tion, the Connors scales have options for multiple in-
formants for both the child and adult scales, adding to
their reliability in multiple settings. For school-aged
children, options include a parent, teacher, and self-
report questionnaire. For adults, options include
a self-report and an observer report. Additionally,
the Conners scales have extensive psychometric data
available and provide subscales beyond attention-
deficit symptomatology that are of interest and
importance in NF, including learning problems, exec-
utive function, and peer relations (table 4). However,
caution is warranted in using the executive function
subscale as a primary outcome variable as it only
correlated significantly with the Plan/Organize scale
of the Behavior Rating Inventory of Executive
Function.33
DISCUSSIONANDFUTUREDIRECTIONS The estab-
lishment of recommendations for a rigorously re-
viewed core test bank of cognitive tests for use in
NF clinical trials is of vital importance given the
morbidity these deficits cause in individuals with
NF1 and the increased focus from the scientific com-
munity on the development of targeted therapies to
ameliorate these impairments. To date, there has been
no systematic review of the psychometric properties
of available cognitive assessment tools specifically
for use in clinical trials in NF1. As we work to pro-
mote the development of novel therapies targeting
cognition in this population, it is imperative that
we prioritize this step. To that end, the REiNS Neu-
rocognitive Committee has taken a systematic,
detailed approach to reviewing available tests of cog-
nition in order to be able to make recommendations
for performance- and observer-based instruments in
clinical trials targeting cognitive deficits. We have
taken guidance from the FDA in our approach,
with the identification of and regulatory approval
of cognitive enhancing agents for NF1 in mind.
In this article, we focused on paper-pencil tools
assessing attention, and our extensive review led us
to recommend DS from the Wechsler scales as the
performance-based outcome measure, and the
Conners scales (Conners 3 for children; CAARS for
adults) as the observer-rated outcome measure. The
recommendations being made are to establish a core
set of tests for use in clinical trials, but are not meant
to preclude individual researchers’ ability to include
other tests relevant to the specific research hypotheses
in the battery of outcome measures for any given trial.
Future articles will provide recommendations for
computerized batteries (including tests of attention)
and tests in other key domains, including executive
function, memory, academic skills, and others.
No single instrument will capture all aspects of
a complex domain or function ideally for all trial de-
signs. However, the DS and Connors scales represent
the ObsRO and PerfO tools that have been reviewed
so far with the best combination of psychometric
properties, patient characteristics, and feasibility for
NF1 clinical trials currently available. Adoption of
these measures in clinical trials of cognitive outcomes
in NF1 will support the development of novel thera-
peutics for cognitive dysfunction in NF1 and lead
to improved impact through the use of consistent,
reliable, and sensitive cognitive outcome measures.
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